InvestorsHub Logo
Post# of 252707
Next 10
Followers 834
Posts 120143
Boards Moderated 17
Alias Born 09/05/2002

Re: biomaven0 post# 214856

Sunday, 11/05/2017 2:47:54 PM

Sunday, November 05, 2017 2:47:54 PM

Post# of 252707
Actually, TEVA has a priority-review voucher for Fremanezumab that was acquired during 3Q17. This was confirmed on the 3Q17 CC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.